pSivida to Present at the 2017 BIO CEO & Investor Conference
February 10 2017 - 7:00AM
pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development
of sustained release drug products, announced today that Nancy
Lurker, President and Chief Executive Officer, is scheduled to
present an overview of the company and its progress at the 19th
Annual BIO CEO & Investor Conference on Tuesday, February 14,
2017, at 8:00 a.m. ET. The conference will be held in New
York, NY.
A live audio and/or webcast and subsequent
archived replay of pSivida’s presentation may be accessed via the
Investors section of the Company’s website under “Resources -
Events & Presentations” at www.psivida.com. The replay will be
available for 90 days after the event.
About pSivida Corp.
pSivida Corp. (www.psivida.com), headquartered
in Watertown, MA, is a leader in the development of sustained
release drug for eye diseases. pSivida has developed three of only
four FDA-approved sustained-release treatments for back-of-the-eye
diseases. The most recent, ILUVIEN®, a micro-insert for diabetic
macular edema, licensed to Alimera Sciences, is currently sold in
the US and three EU countries. Retisert®, an implant for posterior
uveitis, is licensed to and sold by Bausch &
Lomb. pSivida's lead product candidate, Durasert micro-insert
for posterior segment uveitis being independently developed, is
currently in pivotal Phase 3 clinical trials. pSivida's
pre-clinical development program is focused on using its core
platform technologies Durasert™ and Tethadur™ to deliver drugs and
biologics to treat uveitis, wet and dry age-related macular
degeneration, osteoarthritis and other diseases. To learn more
about pSivida, please visit www.psivida.com and connect on Twitter,
LinkedIn, Facebook and Google+.
Contact:
EVC Group
Michael Polyviou/Doug Sherk – Investors
mpolyviou@evcgroup.com; dsherk@evcgroup.com
212.850.6020; 646-445-4800
Thomas Gibson – Media
tom@tomgibsoncommunications.com
201-476-0322
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Apr 2023 to Apr 2024